Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helicobacter pylori eradication therapy for autism symptoms in children and adolescents
IRCT20241211064021N8Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of omeprazole, amoxicillin and metronidazole in Helicobacter pylori infection and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in Childhood Autism Rating Scale score and Helicobacter pylori stool antigen test result. Started May 2025; status: completed.
02
Drugs
omeprazoleamoxicillinmetronidazole
03
Conditions
Helicobacter pylori infectionAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20241211064021N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241211064021N8.